Johnson & Johnson reported first quarter 2026 results that beat Wall Street estimates across the board on Tuesday, posting adjusted earnings per share of $2.70 against an estimate of $2.69 and sales of $24.06 billion against an estimate of $23.66 billion — a revenue beat of $400 million driven by strong outperformance in its pharmaceutical blockbusters Darzalex and Tremfya and solid Medtech segment delivery.
The company also raised its full-year guidance modestly, reflecting confidence in the underlying business trajectory despite a global macroeconomic environment disrupted by the Iran war, Hormuz energy shock, and the resulting pressure on healthcare systems and consumer spending worldwide.
Pharmaceutical highlights
The pharmaceutical segment was the standout driver of the quarter’s revenue beat. Tremfya, J&J’s IL-23 inhibitor used in plaque psoriasis and inflammatory bowel disease, generated revenue of $1.61 billion against an estimate of $1.41 billion — a beat of $200 million or approximately 14% above consensus. The outperformance reflects strong uptake of Tremfya’s expanded indications and its growing position in the competitive immunology market against rivals including AbbVie’s Skyrizi.
Darzalex, J&J’s CD38-directed antibody for multiple myeloma that has become one of the most commercially successful oncology drugs in the world, posted revenue of $3.96 billion against an estimate of $3.84 billion — a beat of $120 million. Darzalex’s consistent outperformance reflects its entrenched position across multiple myeloma treatment lines and its continued penetration into earlier lines of therapy as clinical data supports broader use. At nearly $4 billion in a single quarter, Darzalex is tracking toward an annualised revenue run rate that would make it one of the highest-grossing pharmaceutical products globally.
Medtech segment
J&J’s Medtech segment delivered sales of $8.64 billion against an estimate of $8.55 billion, a modest but clean beat. The segment, which covers surgical instruments, orthopaedics, cardiovascular devices, and vision care, has been navigating a complex environment in which hospital procedure volumes in some markets have been affected by the economic disruption caused by the Iran war’s energy shock. The fact that Medtech beat estimates despite that headwind reflects the resilience of demand for essential medical devices and surgical procedures that cannot be deferred indefinitely.
Full year guidance raised
J&J raised its full-year 2026 guidance on both earnings and sales. Adjusted EPS guidance was lifted to $11.45 to $11.65 from a prior range of $11.43 to $11.63. Adjusted operational EPS guidance was raised to $11.30 to $11.50 from $11.28 to $11.48. Full-year sales guidance was raised to $100.3 billion to $101.3 billion from a prior range of $100 billion to $101 billion — pushing the midpoint of J&J’s annual revenue guidance above $100 billion for the first time, a landmark for one of the world’s largest healthcare companies.
The guidance raise, while modest in absolute terms, signals that J&J’s management sees the Q1 outperformance as durable rather than a one-quarter beat. The pharmaceutical pipeline, Darzalex’s continued trajectory, Tremfya’s expansion, and the Medtech segment’s resilience collectively support a full-year outlook that is tracking slightly ahead of where the company entered 2026.
The macro context
J&J’s Q1 beat is a reminder that large-cap healthcare companies with diversified global revenue streams and essential product portfolios can outperform in difficult macroeconomic environments. While the Iran war and Hormuz energy shock have created significant headwinds for energy-intensive industries, commodity-dependent manufacturers, and consumer discretionary businesses, demand for cancer treatment, autoimmune therapies, and medical devices is structurally less sensitive to crude oil prices and geopolitical volatility than most other sectors. J&J’s ability to raise guidance in the current environment is a function of that structural insulation from the forces currently dominating global markets.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Financial data is sourced from J&J’s official Q1 2026 earnings release. Readers are advised to consult a financial advisor before making any investment decisions. Business Upturn is not responsible for any decisions made based on this article.